While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, adjusted earnings and revenue guidance for the full-year 2025, in line with analysts' estimates.
For fiscal 2025, Eli Lilly now projects earnings in a range of $22.05 to $23.55 per share and adjusted earnings in a range of $22.50 to $24.00 per share on revenues between $58.0 billion and $61.0 billion.
On average, analysts polled expect the company to report earnings of $22.69 per share on revenues of $58.91 billion for the year. Analysts' estimates typically exclude special items.
The company said the growth in revenue compared to 2024 is expected to be largely driven by new Lilly medicines such as Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new indications for existing Lilly medicines; launches of Mounjaro in additional worldwide markets; and potential launches of new medicines such as imlunestrant for metastatic breast cancer.
The company continues to invest heavily in increasing manufacturing capacity and estimates producing at least 1.6 times the amount of salable incretin doses in the first half of 2025, compared to the first half of 2024.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.